Dopa-therapy in the treatment of early stage Parkinson's disease
Broussolle, E.
Revue Neurologique (Paris) 156(2 Part 2): 91-97
2000
ISSN/ISBN: 0035-3787 PMID: 10916042 Document Number: 512731
Document emailed within 1 workday
Related Documents
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Szczudlik, A.; Rudzińska, M. 2007: Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes Neurologia i Neurochirurgia Polska 41(2 Suppl 1: S6-S9
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Selby, G. 1976: The influence of previous stereotactic thalamotomy on l-dopa therapy in Parkinson's disease Proceedings of the Australian Association of Neurologists 13: 55-60
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Lipman, I.J.; Papadopoulos, N.M. 1973: Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy Diseases of the Nervous System 34(1): 59-62
Barbeau, A.; Gillo-Joffroy, L.; Mars, H.; Arsenault, A. 1972: Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602 Revue Canadienne de Biologie 31(Suppl): 169-174
Figuerido, J.A.; De la Herrán, J. 1970: Personal experience in the treatment of Parkinson's disease with L-Dopa Revista Clinica Espanola 119(6): 555-562
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680